Human autologous adipose mesenchymal progenitor cell therapy (Cellular Biomedicine Group)

自体人源脂肪间充质祖细胞（西比曼生物）

Report date: 2023/01/12 15:29:56

Base Information

Drug NameHuman autologous adipose mesenchymal progenitor cell therapy (Cellular Biomedicine Group)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsOsteoarthritis, Knee
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesWuxi Sebiman Biotechnology Co LtdCellular Biomedicine (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesWuxi Sebiman Biotechnology Co LtdCellular Biomedicine (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsOsteoarthritis, Knee
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A